GRIFOLS’ PLASMA WORTH A SHOT (BUY; 27% UPSIDE)
17/09/20 -"Since our last Teaser in May 2019, it has been a rollercoaster ride for Grifols (Buy, Spain), a leading player in the $23bn oligopolistic plasma marketplace. While the FDA approval for the ..."
Pages
54
Language
English
Published on
17/09/20
You may also be interested by these reports :
24/10/25
The Q3 operating profitability came in considerably ahead of the street’s estimates, though sales met expectations. The performance was driven by ...
23/10/25
The Q3 sales missed expectations by a small margin; however, the management upgraded its 2025 earnings outlook. The Pharmaceuticals segment was again ...
23/10/25
Lonza’s strong Q3 commentary reaffirmed its commitment to meeting the 2025 guidance, boosting investor sentiment. While operational figures were not ...
22/10/25
Ipsen’s Q3 sales surpassed expectations, showing robust growth across all segments. Consequently, the 2025 guidance has been revised upwards. The ...